ASND announces broader U.S. dosing ranges for SKYTROFA (TransCon hGH)

Rhea-AI Filing Summary

Ascendis Pharma (ASND) reported a product update via Form 6-K. The company announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States. The therapy is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

The report is also incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2025

Commission File Number: 001-36815

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916 and 333-285322) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (together with its subsidiaries, the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On October 22, 2025, the Company announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: October 22, 2025				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

FAQ

What did Ascendis Pharma (ASND) announce in this 6-K?

Ascendis announced commercial availability of SKYTROFA (TransCon hGH) in broader dosing ranges in the United States for adults with growth hormone deficiency.

What is SKYTROFA (TransCon hGH) used for?

It is used for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Where are the broader dosing ranges of SKYTROFA available?

In the United States.

Does the 6-K affect existing registration statements?

Yes. The report is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.

What is the form type of this filing for Ascendis Pharma (ASND)?

Form 6-K, a report of a foreign private issuer.

Does the filing disclose financial figures or sales data?

No financial figures are disclosed in the provided content.